期刊文献+

甲钴胺防治长春新碱神经毒性临床观察 被引量:5

Clinical Observation of the Effect of Methylcobalamin in the Prevention and Treatment of Vincristine-induced Nerve Toxicity
暂未订购
导出
摘要 目的:观察甲钴胺防治长春新碱神经毒性的近期疗效。方法:入选54例患者随机分为A、B两组,两组化疗方案均为含长春新碱1 mg/m2的化疗方案,21 d为1周期。A组(试验组)采用甲钴胺+化疗,B组(对照组)单用化疗。A组在用长春新碱之前口服甲钴胺片0.5 mg/次,每日3次,第1~7 d,所有患者完成4周期化疗后评价疗效。结果:可评价病例54例,A组28例,发生神经毒性1级4例、2级2例、3级1例,总发生率25.0%。B组26例,发生神经毒性1级9例、2级4例、3级4例,总发生率65.4%。两组比较,差异有统计学意义(P〈0.05)。结论:甲钴胺能降低长春新碱神经毒性的发生率,值得临床推广应用。 Objective: To observe the short-term curative effect of methylcobalamin in preventing and treating vincristine-induced nerve toxicity. Methods: 54 patients were divided into two groups at random. Both the groups were given the same chemical treatment project of vincristine( 1. 4 mg / m2),with a treatment period of 21 days. The patients in Group A( experiment group) were given methylcobalamin in addition to chemical treatment of vincristine and those in Group B( control group) were given chemical treatment of vincristine only. The patients in Group A took oral methylcobalamin tablet( 0. 5 mg / once,three times a day) for first 7 days before taking vincristine in every treatment period. The curative effect assessment was given to all the patients in both the groups by the end of the four treatment periods. Results: Of 54 cases evaluated( 28 in Group A,26 in Group B),7 cases of nerve toxicity occurred in Group A( Grade Ⅰ 4,Grade Ⅱ 2,Grade Ⅲ 1),with a total occurrence of 25. 0 %; 17 cases of nerve toxicity occurred in Group B,with a total occurrence rate of 65. 4 %. There was obvious difference between the two groups( P 0. 05). Conclusion: Methylcobalamin can reduce the development of the nerve toxicity induced by vincristine and can be widely applied to clinical practice.
出处 《包头医学院学报》 CAS 2014年第2期53-54,共2页 Journal of Baotou Medical College
关键词 甲钴胺 长春新碱 神经毒性 Methylcobalamin Vincristine Nerve toxicity
  • 相关文献

参考文献6

二级参考文献13

  • 1李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:868
  • 2孙燕,临床肿瘤内科手术 第3版(第3版),1996年,33-101,214-215页
  • 3Aley K, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience, 1996,73:259 265.
  • 4Tanner K D, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci, 1998, 18: 6480-6491.
  • 5Nozaki-Taguchi N, Chaplan SR, Higuera ES, et al. Vincristine-induced allodynia in the rat. Pain, 2001, 93:69 -76.
  • 6Colburn RW, DeLeo JA, Rickman AJ, et al. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J Neuroimmunol, 1997, 79 : 163 - 175.
  • 7Casey EB, Jellife AM, Le Quesne PM, et al. Vincristine neuropathy. Clinical and electrophysiological observations. Brain, 1973,96:69 - 86.
  • 8Kaplan RS, Wiernick PH. Neurotoxicity of antineoplasic drugs. Semin Oncol, 1982,9 : 103 - 130.
  • 9MacFarlane BV, Wright A, Benson HAE. Reversible blockade of retrograde axonal transport in the rat sciatic nerve by vincristine. J Pharm Pharmacol, 1997,49:97 - 101.
  • 10Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol, 2000,424:563 - 576.

共引文献377

同被引文献59

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部